Literature DB >> 1348155

An immunohistological demonstration of c-erbB-2 oncoprotein expression in primary urothelial bladder cancer.

R A Gardiner1, M L Samaratunga, M D Walsh, G J Seymour, M F Lavin.   

Abstract

Sections of formalin-fixed, paraffin-blocked tissue from 116 primary transitional cell carcinomas were stained immunohistochemically using a polyclonal antibody against the c-erbB-2 oncoprotein. Positive staining of cell membranes, known to correlate with gene amplification, was seen in 22 (19%) of the 116, with variable staining from tumour to tumour and within tumours themselves. Consistent with its mooted value as a prognosticator in bladder cancer, the c-erbB-2 oncoprotein was detected in 13 (of 40) grade III and 9 of the 26 muscle-invasive tumours examined compared to 1 (of 25) grade I and 6 (of 66) mucosa only (pTa) lesions. These results support further examination of c-erbB-2 expression in bladder cancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1348155     DOI: 10.1007/bf00296522

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  15 in total

1.  The epidermal growth factor receptor and the prognosis of bladder cancer.

Authors:  D E Neal; L Sharples; K Smith; J Fennelly; R R Hall; A L Harris
Journal:  Cancer       Date:  1990-04-01       Impact factor: 6.860

2.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

3.  Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor.

Authors:  T Yamamoto; S Ikawa; T Akiyama; K Semba; N Nomura; N Miyajima; T Saito; K Toyoshima
Journal:  Nature       Date:  1986 Jan 16-22       Impact factor: 49.962

4.  Immunocytochemical demonstration of p21ras in normal and transitional cell carcinoma urothelium.

Authors:  T L Dunn; G J Seymour; R A Gardiner; G M Strutton; M F Lavin
Journal:  J Pathol       Date:  1988-09       Impact factor: 7.996

5.  Expression of the c-erbB-2 proto-oncogene protein in human breast cancer.

Authors:  W J Gullick
Journal:  Recent Results Cancer Res       Date:  1989

6.  EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling.

Authors:  P P Di Fiore; O Segatto; W G Taylor; S A Aaronson; J H Pierce
Journal:  Science       Date:  1990-04-06       Impact factor: 47.728

7.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

8.  Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification.

Authors:  D J Venter; N L Tuzi; S Kumar; W J Gullick
Journal:  Lancet       Date:  1987-07-11       Impact factor: 79.321

9.  Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading.

Authors:  M S Berger; G W Locher; S Saurer; W J Gullick; M D Waterfield; B Groner; N E Hynes
Journal:  Cancer Res       Date:  1988-03-01       Impact factor: 12.701

10.  c-erbB-2 expression in benign and malignant breast disease.

Authors:  B A Gusterson; L G Machin; W J Gullick; N M Gibbs; T J Powles; C Elliott; S Ashley; P Monaghan; S Harrison
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

View more
  2 in total

Review 1.  Molecular biology of dissemination in bladder cancer--laboratory findings and clinical significance.

Authors:  B J Schmitz-Dräger; F Jankevicius; R Ackermann
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

2.  Multiplatform Biomarker Discovery for Bladder Cancer Recurrence Diagnosis.

Authors:  Marine De Paoli; Selma Gogalic; Ursula Sauer; Claudia Preininger; Hardev Pandha; Guy Simpson; Andras Horvath; Christophe Marquette
Journal:  Dis Markers       Date:  2016-08-31       Impact factor: 3.434

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.